On October 15, 2026 CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer ("mCRC") and metastatic triple-negative breast cancer ("mTNBC"), reported it will host an investor webcast on October 19, 2026, at 1 p.m. PT, to provide a corporate and clinical update.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The investor webcast will highlight CytoDyn’s latest scientific, clinical, operational, and financial progress, as well as calendar 2026 priorities and upcoming milestones. Dr. Jacob P. Lalezari, CEO of CytoDyn, will be joined by Robert E. Hoffman, CFO of CytoDyn, and Pashtoon M. Kasi, M.D., M.S., Medical Director of GI Oncology, City of Hope Orange County, Irvine, California. Reny Aniline, Senior Director of BioPharma Business Development of Natera, Inc., will also participate in the webcast to discuss the recently announced strategic collaboration between Natera and CytoDyn, and to provide further context on the early ctDNA observations in CytoDyn’s CLOVER study.
Date: Monday, October 19, 2026
Time: 1 p.m. PT
Registration and Access Link
This is a livestream presentation. Attendees are advised to log in ahead of the start time. The Company will host a live Q&A session during the webcast; questions may be submitted in advance to [email protected].
Following the conclusion of the webcast, a replay will be available for approximately 30 days in the investor relations section of the Company’s website.
(Press release, CytoDyn, OCT 15, 2026, View Source [SID1234673485])